Evaluation of the Molecular Size Distribution of Rabies Immunoglobulin Using High-Performance Liquid Chromatography

Rabies immunoglobulin is one of the most commonly used antiviral serum drugs. In the Russian Federation, more than 400,000 people are at risk of contracting rabies every year. In order to improve the drug safety when using heterologous immunoglobulin, it is advisable to introduce such a quality indicator as molecular size distribution. This indicator reflects the distribution of single immunoglobulin molecules, their dimers, aggregates, and fragments in the drug. The study of the content of these fractions in the drug using high-performance liquid chromatography is determined by the requirements of the XIV edition of the State Pharmacopoeia of the Russian Federation. The aim of the present study was to establish the conditions for high-performance liquid chromatography when determining the molecular size distribution of heterologous rabies immunoglobulin. A method for determining the indicator of molecular size distribution using a BioSep-SEC-s3000 (“Phenomenex Inc.”, USA) column and a Biologic Duoflow (“BioRad”, USA) chromatographic system is proposed. Commercial and experimental samples of rabies immunoglobulin obtained from horse blood serum were used. When studying chromatographic parameters (resolution between peaks, retention time, peak symmetry, etc.), analysis conditions in accordance with the pharmacopoeial requirements were selected. The resolution values were: between the peaks of monomers and dimers — 1.42; between the peaks of aggregates and monomers – 3.9, between the peaks of monomers and fragments – at least 4.46. The experiment showed the specificity and repeatability of the technique. Additionally, a high degree of purification of the studied commercial samples of rabies immunoglobulin was shown, which is characterized by the absence of fractions of aggregates and fragments. The results obtained allow us to conclude that the proposed method can be used using a BioSep-SEC-s3000 column and a Biologic Duoflow chromatographic system to control the quality of heterologous rabies immunoglobulin in terms of molecular size distribution.

1. Abramova E.G., Nikiforov A.K., Kireev M.N., Kochkalova N.N., Generalov S.V., Selezneva A.G., Savitskaya L.V., Ivanov Yu.V. Opredelenie molekulyarnykh parametrov preparata geterologichnogo antirabicheskogo immunoglobulina metodom gel'-fil'tratsii [Determination of the molecular parameters of heterologous anti-rabies immunoglobulin using gel-filtration]. Problemy osobo opasnykh infektsiy [Problems of Particularly Dangerous Infections]. 2010;106(4):54–57. (In Russian) DOI: 10.21055/0370-1069-2010-4(106)-54-57

2. Melnikov S.A., Borisevich I.V., Rozhdestvensky E.V., Pantyukhov V.B., Chernikova N.K., Gordeev E.V., Nimirskaya S.A., Khmelev A.L., Syromyatnikova S.I., Shatokhina I.V., Plekhano-va T.M., Timankova G.D., Borisevich S.V., Kutaev D.A., Stovba L.F., Mishalova E.Yu. Svoystva geterologichnogo immunoglobulina protiv likhoradki Ebola posle dlitel'nogo khraneniya [Properties of heterologous anti-ebola immunoglobulin after long storage]. BIOpreparaty. Profilaktika, diagnostika, lechenie [BIOpreparations. Prevention, Diagnosis, Treatment]. 2020;20(1):50–59. (In Russian) DOI: 10.30895/2221-996X-2020-20-1-50-59

3. Mishalova Е.Yu., Gordeev E.V., Lebedev V.N., Melnikov S.A., Nimirskaya S.A., Borisevich S.V. Aprobatsiya metodiki eksklyuzionnoy khromatografii dlya otsenki molekulyarnykh parametrov immunoglobulina protiv likhoradki Ebola iz syvorotki krovi loshadey [Experimental testing of a size-exclusion chromatography method used for evaluation of molecular parameters of equine anti-Ebola immunoglobulin]. BIOpreparaty. Profilaktika, diagnostika, lechenie [BIOpreparations. Prevention, Diagnosis, Treatment]. 2019;19(4):261–267. (In Russian) DOI: 10.30895/2221-996X-2019-19-4-261-267

4. Movsesyants A.A., Butyrskiy A.Yu., Bondarev V.P., Olefir Yu.V., Postnova E.L., Mukhacheva A.V. Kvoprosu o primenenii geterologichnogo antirabicheskogo immunoglobulina dlya spetsificheskoy profilaktiki beshenstva u lyudey [On the issue of using heterologous antirabies immunoglobulin for specific prophylaxis of rabies in humans]. Epidemiologiya i vaktsinoprofilaktika [Epidemiology and Vaccinal Prevention]. 2015;14(5):85–89. (In Russian) DOI: 10.31631/2073-3046-2015-14-5-85-89

5. Registr lekarstvennykh sredstv Rossii [Register of Medicines of the Russian Federation]. (In Russian)

6. Repina I.B., Feklisova L.V., Sklyar L.F., Ushakova A.Yu., Rossoshanskaya N.V., Solovyova N.P. Beshenstvo: obzor literatury i sluchay iz praktiki. [Rabies: literature review and case study]. Meditsinskiy opponent [Medical Opponent]. 2023;3(23):73–80. (In Russian).

7. Choi C.W., Jang W., Shim S.B., Song H.J., Cho J., Moon H., Park S.M., Han K., Sohn K.H. Collaborative study for the establishment of national reference standard for molecular size distribution test of human immunoglobulin products. Yahhak HoeJi. 2021;65:223– 227. DOI: 10.17480/psk.2021.65.3.223

8. Christians S., Schluender S., van Treel N.D., BehrGross M.E. Interpretation of size-exclusion chromatography for the determination of molecular-size distribution of human immunoglobulins. Pharmeuropa Bio & Scientific Notes. 2016;2016:115–128.

9. Human normal immunoglobulin (intramuscular administration), monograph 0338. Ph. Eur. 11th ed. Strasbourg, France: Council of Europe, 2023.

10. Jiskoot W., Randolph T.W., Volkin D.B., Middaugh C.R., Schöneich C., Winter G., Friess W., Crommelin D.J., Carpenter J.F. Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release. J. Pharm. Sci. 2012;101(3):946–954. DOI: 10.1002/jps.23018

11. Lee J.K., Deluccia F.J., Kelly E.L., Davidson C., Borger F.R. Determination of the molecular size distribution of immunoglobulin G (IgG) in intravenous IgG-albumin formulations by high-performance liquid chromatography. J. Chromatogr. 1988;444:141–152. DOI: 10.1016/s0021-9673(01)94017-8

12. Roberts C.J. Therapeutic protein aggregation: Mechanisms, design, and control. Trends Biotechnol. 2014;32(7):372–380. DOI: 10.1016/j. tibtech.2014.05.005

13. Woznichak M., Vandeberg P., Russ C., Talton Ch., Srivastava J., Arora V., Merritt W.K., Jose M. Application of a caprylate/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma. J. Immunol. Methods. 2021;499:113–164. DOI: 10.1016/j.jim.2021.113164

14. Wang H., Levi M.S., Del Grosso A.V., McCormick W.M., Bhattacharyya L. An improved size exclusion-HPLC method for molecular size distribution analysis of immunoglobulin G using sodium perchlorate in the eluent. J. Pharm. Biomed. Anal. 2017;138:330–343. DOI: 10.1016/j.jpba.2017.02.025